GBMs with an oligodendroglioma component were also dismissed from the classification at this point1, which might have been partly due to the low proportion of 1p19q codeleted cases among these GBM patients as well as the strong influence of the IDH mutation and MGMT methylation status on patient prognosis6, 7. This evidence concerns the gene IDH2 and oligodendroglioma.